SCHEMBL30155768

SCHEMBL30155768

COCCNc1cccc2c1CN(C(=O)c1c(O)cc(O)cc1OCc1ccccc1)CC2

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 6/20 0.40
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
GPR183 P32249 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
RECQL P46063 1/20 0.36
ADRA1A P35348 1/20 0.36
CHRNA7 P36544 2/20 0.36
SPR P35270 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24914227 1.00 PTGDR2 (0.40) PTGDR2TMEM97SIGMAR1GPR183L3MBTL1
SCHEMBL31013792 0.91 PTGDR2 (0.38) PTGDR2TMEM97SIGMAR1GPR183RECQL
SCHEMBL30155708 0.88 TMEM97 (0.42) PTGDR2TMEM97SIGMAR1GPR183L3MBTL1
SCHEMBL24914220 0.88 TMEM97 (0.42) PTGDR2TMEM97SIGMAR1GPR183L3MBTL1
SCHEMBL29168641 0.86 BRD4 (0.47) PTGDR2TMEM97SIGMAR1GPR183L3MBTL1
SCHEMBL24913997 0.83 TMEM97 (0.42) PTGDR2TMEM97SIGMAR1GPR183L3MBTL1
SCHEMBL30155597 0.83 TMEM97 (0.42) PTGDR2TMEM97SIGMAR1GPR183L3MBTL1
SCHEMBL24913940 0.83 TMEM97 (0.42) PTGDR2TMEM97SIGMAR1L3MBTL1SPR
SCHEMBL30155595 0.83 TMEM97 (0.42) PTGDR2TMEM97SIGMAR1L3MBTL1SPR
SCHEMBL30155738 0.82 HSP90AA1 (0.39) PTGDR2GPR183L3MBTL1RECQLCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293392-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-09-05 US claimed
CN-117693507-A Inhibitor compounds 奈奥芬莱有限公司 2024-03-12 CN claimed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 WO claimed
US-20240293392-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-09-05 US disclosed
CN-117693507-A Inhibitor compounds 奈奥芬莱有限公司 2024-03-12 CN disclosed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293392-A1 INHIBITOR COMPOUNDS MSH2, PMS2, MSH6 PTGDR2 1004/4885TMEM97 3224/4885SIGMAR1 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.